Cytokinetics (NASDAQ:CYTK) Hits New 52-Week Low – Here’s What Happened

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Monday. The stock traded as low as $53.40 and last traded at $54.08, with a volume of 207,722 shares traded. The stock had previously closed at $56.13.

Analyst Ratings Changes

A number of equities analysts recently commented on CYTK shares. William Blair started coverage on shares of Cytokinetics in a research note on Friday, October 16th. They set an “outperform” rating for the company. Needham & Company LLC increased their target price on Cytokinetics from $102.00 to $112.00 and gave the company a “buy” rating in a report on Friday, August 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Cytokinetics in a research note on Friday, September 11th. Citigroup lifted their price target on Cytokinetics from $99.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Finally, UBS Group reaffirmed a “buy” rating and set a $104.00 price objective on shares of Cytokinetics in a research report on Wednesday, October 14th. Nineteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $106.67.

Read Our Latest Research Report on Cytokinetics

Cytokinetics Stock Down 5.1%

The business’s fifty day simple moving average is $64.11 and its two-hundred day simple moving average is $69.78. The company has a market cap of $7.42 billion, a price-to-earnings ratio of -8.82 and a beta of 0.45.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) earnings per share for the quarter, topping the consensus estimate of ($1.43) by $0.06. The company had revenue of $47.56 million for the quarter, compared to analysts’ expectations of $41.88 million. During the same quarter in the prior year, the firm posted ($2.55) EPS. The firm’s quarterly revenue was up 2356.5% compared to the same quarter last year. Sell-side analysts predict that Cytokinetics, Incorporated will post -5.85 EPS for the current fiscal year.

Insider Activity at Cytokinetics

In other Cytokinetics news, CEO Robert Blum sold 7,500 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $62.81, for a total value of $471,075.00. Following the completion of the transaction, the chief executive officer owned 278,544 shares in the company, valued at $17,495,348.64. This represents a 2.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert E. Landry sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $72.13, for a total value of $72,130.00. Following the transaction, the director directly owned 8,184 shares in the company, valued at approximately $590,311.92. The trade was a 10.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 178,426 shares of company stock valued at $12,208,290 over the last quarter. 2.60% of the stock is owned by insiders.

Institutional Trading of Cytokinetics

Institutional investors and hedge funds have recently made changes to their positions in the company. CSM Advisors LLC boosted its position in shares of Cytokinetics by 62.6% in the 3rd quarter. CSM Advisors LLC now owns 29,406 shares of the biopharmaceutical company’s stock valued at $1,939,000 after purchasing an additional 11,320 shares during the period. Cetera Investment Advisers grew its stake in Cytokinetics by 31.2% during the 3rd quarter. Cetera Investment Advisers now owns 17,354 shares of the biopharmaceutical company’s stock worth $1,144,000 after buying an additional 4,122 shares during the last quarter. Jump Financial LLC purchased a new position in Cytokinetics during the 3rd quarter worth approximately $14,556,000. Checkpoint Capital L.P. increased its position in Cytokinetics by 8.9% during the third quarter. Checkpoint Capital L.P. now owns 517,278 shares of the biopharmaceutical company’s stock worth $34,094,000 after buying an additional 42,278 shares during the period. Finally, Pathstone Holdings LLC increased its position in Cytokinetics by 2.1% during the third quarter. Pathstone Holdings LLC now owns 48,642 shares of the biopharmaceutical company’s stock worth $3,206,000 after buying an additional 1,009 shares during the period.

About Cytokinetics

(Get Free Report)

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.

Featured Articles

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.